Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations

(2017) Nourah Obaid et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma

(2017) Chunyan Hao et al.   MEDICINE

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma

(2017) Hilary R. Keller et al.   Oncotarget

Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM

(2016) Leona Rohrbeck et al.   CELL DEATH AND DIFFERENTIATION

Metastatic melanoma treatment: Combining old and new therapies

(2016) Ryan J. Davey et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The role of mitogen-activated protein targeting in melanoma beyond BRAFV600

(2016) Ryan J. Sullivan   CURRENT OPINION IN ONCOLOGY

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

(2016) Georgina V Long et al.   LANCET ONCOLOGY

A tale of the epidermal growth factor receptor: The quest for structural resolution on cells

(2016) Christopher J. Tynan et al.   METHODS

Metastatic Melanoma – A Review of Current and Future Treatment Options

(2015) E Maverakis et al.   ACTA DERMATO-VENEREOLOGICA

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Treatment of NRAS-Mutant Melanoma

(2015) Douglas B. Johnson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas

(2015) Jinhua Wang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion

(2015) Hui-Hui Cao et al.   Molecular Cancer

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy

(2015) R Mandal et al.   ONCOGENE

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

Focus on PTEN regulation

(2015) Miriam Bermúdez Brito   Frontiers in Oncology

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

(2015) Ryan B. Corcoran et al.   Oncotarget

Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032

(2015) Elisabetta Vergani et al.   NEOPLASIA

Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway

(2014) Chun-Han Hou et al.   BIOCHEMICAL PHARMACOLOGY

Targeting c-Met in melanoma

(2014) Deven Etnyre et al.   CANCER BIOLOGY & THERAPY

Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors

(2014) Lydia W.T. Cheung et al.   CANCER CELL

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma

(2014) Ahmad A Tarhini et al.   Journal of Translational Medicine

High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients

(2014) Taro Masaki et al.   Pigment Cell & Melanoma Research

The melanoma revolution: From UV carcinogenesis to a new era in therapeutics

(2014) J. A. Lo et al.   SCIENCE

BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling

(2014) B. Sanchez-Laorden et al.   Science Signaling

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma

(2014) Marian M. Deuker et al.   Cancer Discovery

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling

(2014) M. Will et al.   Cancer Discovery

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Update on the Targeted Therapy of Melanoma

(2013) Douglas B. Johnson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

UVB-Stimulated TNFα Release from Human Melanocyte and Melanoma Cells Is Mediated by p38 MAPK

(2013) Visalini Muthusamy et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma

(2013) Ao-Xue Wang et al.   IUBMB LIFE

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells

(2013) D. Beck et al.   Science Signaling

Challenging resistance mechanisms to therapies for metastatic melanoma

(2013) Lucio Tentori et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors

(2013) Clare J. Stones et al.   Frontiers in Genetics

Skin Cancer: An Overview of Epidemiology and Risk Factors

(2013) Randy Gordon   Seminars in Oncology Nursing

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

(2012) Ji Eun Kim et al.   BMC CANCER

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

(2012) Vipin Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Melanoma Genetics: Recent Findings Take Us Beyond Well-Traveled Pathways

(2012) Matthew H. Law et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29

(2012) Karen Tumaneng et al.   NATURE CELL BIOLOGY

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

(2012) Britta Weigelt et al.   Frontiers in Oncology

Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma

(2011) Yasser Heakal et al.   ANNALS OF PHARMACOTHERAPY

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Association of activated c-Met with NRAS-mutated human melanomas

(2011) Chandrani Chattopadhyay et al.   INTERNATIONAL JOURNAL OF CANCER

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

The Mechanisms of UV Mutagenesis

(2011) Hironobu IKEHATA et al.   JOURNAL OF RADIATION RESEARCH

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Effect of Novel Marine Nutraceuticals on IL-1α-Mediated TNF-αRelease from UVB-Irradiated Human Melanocyte-Derived Cells

(2011) Visalini Muthusamy et al.   Oxidative Medicine and Cellular Longevity

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA

(2010) Angela M. Keuling et al.   Pigment Cell & Melanoma Research

The UV response of the skin: a review of the MAPK, NFκB and TNFα signal transduction pathways

(2009) Visalini Muthusamy et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas

(2009) Y. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis

(2008) Vasileia-Ismini Alexaki et al.   Pigment Cell & Melanoma Research